{"id":"tp-61713","type":"article-newspaper","title":"Celldex Shares Slip 2% After Barzolvolimab Misses Goals in Atopic Dermatitis Trial","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/61713","datePublished":"2026-11-19T22:17:54.000Z","dateModified":"2026-11-19T22:17:54.000Z","language":"en","abstract":"A phase 2 atopic dermatitis study of barzolvolimab missed its primary and secondary endpoints. Celldex shares fell about 2% in after-hours trading Thursday, Nov. 19.","section":"Business","references":[]}